ReviewNature reviews. Clinical oncology2020
All change in the prostate cancer diagnostic pathway.
Review in Nature reviews. Clinical oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06360523 (ProstateAI - A Prospective Paired Validating Cohort Study to Evaluate an MRI-based Optimized Prostate Cancer Diagnostic Pathway Powered by Artificial Intelligence), which is not on this map. Cited by 52 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
ProstateAI - A Prospective Paired Validating Cohort Study to Evaluate an MRI-based Optimized Prostate Cancer Diagnostic Pathway Powered by Artificial Intelligence
Who cites it
52 citing papers in PubMed, 1 synthesis or guideline pooled it, 113 citations in OpenAlex.
- Interobserver Agreement and Accuracy in Interpreting mpMRI of the Prostate: a Systematic Review.Current urology reports · 2022Pooled it
- 3,3'-Di-O-methylellagic Acid Isolated fromPharmaceuticals (Basel, Switzerland) · 2026Article
- Clinically significant prostate cancer detection with deep learning in a multi-center magnetic resonance imaging study.Scientific reports · 2026Article
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.JAMA network open · 2026Article
- Cost-effectiveness analysis of a biopsy-free diagnostic strategy for prostate cancer using mpMRI and PSMA-PET/CT.BJUI compass · 2026Article
- Clinical value of emerging peripheral blood protein biomarkers in prostate cancer (Review).Oncology letters · 2026Review
- The role of microrna-346 in prostate cancer progression: Clinical significance and biomarker potential.Journal of medical biochemistry · 2025Article
- Article
- A sensitive and specific non-invasive urine biomarker panel for prostate cancer detection.EBioMedicine · 2025Article
- A Multimarker Model for Prostate Cancer Risk Assessment: Improving Diagnostic Accuracy Beyond PSA.The Prostate · 2025Article
- Deep Learning Classification of Prostate Cancer Using MRI Histopathologic Data.Radiology. Imaging cancer · 2025Article
- Artificial Intelligence-Assisted Segmentation of Prostate Tumors and Neurovascular Bundles: Applications in Precision Surgery for Prostate Cancer.Annals of surgical oncology · 2025Article
- Role of region-of-interest magnetic resonance imaging fusion biopsy in mitigating overtreatment of localized prostate cancer - A retrospective cohort study.European journal of radiology open · 2025Article
- Article
- Advance in prostate cancer biomarker discovery: bridging detection, prognosis and therapeutics.Discover oncology · 2025Review
- Fusion MRI/Ultrasound-Guided Transperineal Biopsy: A Game Changer in Prostate Cancer Diagnosis.Journal of clinical medicine · 2025Review
- Advances in the identification of novel cell signatures in benign prostatic hyperplasia and prostate cancer using single-cell RNA sequencing.Frontiers in immunology · 2025Review
- Development and validation of a clinical-radiomics model for prediction of prostate cancer: a multicenter study.World journal of urology · 2024Article
- Diagnostic performance ofOncology letters · 2024Article
- The impact of pre-biopsy MRI and additional testing on prostate cancer screening outcomes: A rapid review.BJUI compass · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 2 countries.
Funding
Abstract
Following detection of high levels of serum prostate-specific antigen, many men are advised to have transrectal ultrasound-guided biopsy in an attempt to locate a cancer. This nontargeted approach lacks accuracy and carries a small risk of potentially life-threatening sepsis. Worse still, it can detect clinically insignificant cancer cells, which are unlikely to be the origin of advanced-stage disease. The detection of these indolent cancer cells has led to overdiagnosis, one of the major problems of contemporary medicine, whereby many men with clinically insignificant disease are advised to undergo unnecessary radical surgery or radiotherapy. Advances in imaging and biomarker discovery have led to a revolution in prostate cancer diagnosis, and nontargeted prostate biopsies should become obsolete. In this Perspective article, we describe the current diagnostic pathway for prostate cancer, which relies on nontargeted biopsies, and the problems linked to this pathway. We then discuss the utility of prebiopsy multiparametric MRI and novel tumour markers. Finally, we comment on how the incorporation of these advances into a new diagnostic pathway will affect the current risk-stratification system and explore future challenges.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.